US20010006635A1 - Use of heparinase to decrease inflammatory responses - Google Patents

Use of heparinase to decrease inflammatory responses Download PDF

Info

Publication number
US20010006635A1
US20010006635A1 US08/722,659 US72265996A US2001006635A1 US 20010006635 A1 US20010006635 A1 US 20010006635A1 US 72265996 A US72265996 A US 72265996A US 2001006635 A1 US2001006635 A1 US 2001006635A1
Authority
US
United States
Prior art keywords
heparinase
heparin
endothelium
tissue
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US08/722,659
Other languages
English (en)
Inventor
D. Clark Bennett
Elizabeth Cauchon
Dominique Fink
Brigette Grouix
Ariane Hsia
Pamela Danagher
Joseph Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES96936052T priority Critical patent/ES2227611T3/es
Priority to AT96936052T priority patent/ATE273020T1/de
Application filed by Individual filed Critical Individual
Priority to JP51372397A priority patent/JP3713276B2/ja
Priority to PT96936052T priority patent/PT852491E/pt
Priority to DK96936052T priority patent/DK0852491T3/da
Priority to EP04076600A priority patent/EP1552846A3/de
Priority to CA002233343A priority patent/CA2233343A1/en
Priority to DE69633127T priority patent/DE69633127T2/de
Priority to PCT/US1996/015593 priority patent/WO1997011684A1/en
Priority to AU73791/96A priority patent/AU703394B2/en
Priority to EP96936052A priority patent/EP0852491B1/de
Priority to US08/722,659 priority patent/US20010006635A1/en
Assigned to IBEX TECHNOLOGIES INC. reassignment IBEX TECHNOLOGIES INC. SEE RECORDING AT REEL 8857, FRAME 0657. (RE-RECORDED TO CORRECT SERIAL NUMBER) Assignors: GROUIX, BRIGETTE, HSIA, ARIANE, ZIMMERMANN, JOSEPH, DANAGHER, PAMELA, BENNETT, D. CLARK, CAUCHON, ELIZABETH, FINK, DOMINIQUE
Assigned to IBEX TECHNOLOGIES INC. reassignment IBEX TECHNOLOGIES INC. RECORD TO CORRECT SERIAL NUMBER PREVIOUSLY RECORDED ON REEL 8623 FRAME 914. Assignors: GROUIX, BRIGETTE, HSIA, ARIANE, ZIMMERMANN, JOSEPH, DANANAGHER, PAMELA, BENNETT, D. CLARK, CAUCHON, ELIZABETH, FINK, DOMINIQUE
Publication of US20010006635A1 publication Critical patent/US20010006635A1/en
Assigned to BIOMARIN PHARMACEUTICALS INC. reassignment BIOMARIN PHARMACEUTICALS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOMARIN ENZYMES, INC.
Assigned to BIOMARIN PHARMACEUTICAL INC. reassignment BIOMARIN PHARMACEUTICAL INC. CORRECT COVER SHEET TO CORRECT SERIAL NUMBER, PREVIOUSLY RECORDED AT REEL/FRAME 014405/0059 (ASSIGNMENT OF ASSIGNOR'S INTEREST) Assignors: BIOMARIN ENZYMES, INC.
Priority to US11/118,477 priority patent/US20050191288A1/en
Priority to US11/357,967 priority patent/US7264799B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
US08/722,659 1995-09-29 1996-09-27 Use of heparinase to decrease inflammatory responses Abandoned US20010006635A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EP96936052A EP0852491B1 (de) 1995-09-29 1996-09-27 Verwendung von heparinasen zur verminderung von entzündungsreaktionen
AU73791/96A AU703394B2 (en) 1995-09-29 1996-09-27 Use of heparinases to decrease inflammatory responses
US08/722,659 US20010006635A1 (en) 1995-09-29 1996-09-27 Use of heparinase to decrease inflammatory responses
AT96936052T ATE273020T1 (de) 1995-09-29 1996-09-27 Verwendung von heparinasen zur verminderung von entzündungsreaktionen
DK96936052T DK0852491T3 (da) 1995-09-29 1996-09-27 Anvendelse af heparinaser til at mindske inflammatoriske responser
EP04076600A EP1552846A3 (de) 1995-09-29 1996-09-27 Verwendung von Heparinasen zur Verminderung von Entzündungsreaktionen
CA002233343A CA2233343A1 (en) 1995-09-29 1996-09-27 Use of heparinases to decrease inflammatory responses
DE69633127T DE69633127T2 (de) 1995-09-29 1996-09-27 Verwendung von heparinasen zur verminderung von entzündungsreaktionen
PCT/US1996/015593 WO1997011684A1 (en) 1995-09-29 1996-09-27 Use of heparinases to decrease inflammatory responses
ES96936052T ES2227611T3 (es) 1995-09-29 1996-09-27 Uso de heparinas para disminuir repuestas inflamatorias.
PT96936052T PT852491E (pt) 1995-09-29 1996-09-27 Utilizacao de heparinases para diminuir respostas inflamatorias
JP51372397A JP3713276B2 (ja) 1995-09-29 1996-09-27 炎症反応の軽減のためのヘパリナーゼの使用
US11/118,477 US20050191288A1 (en) 1995-09-29 2005-05-02 Use of heparinase to decrease inflammatory responses
US11/357,967 US7264799B2 (en) 1995-09-29 2006-02-22 Use of heparinases to decrease inflammatory response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US462295P 1995-09-29 1995-09-29
US08/722,659 US20010006635A1 (en) 1995-09-29 1996-09-27 Use of heparinase to decrease inflammatory responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/118,477 Continuation US20050191288A1 (en) 1995-09-29 2005-05-02 Use of heparinase to decrease inflammatory responses

Publications (1)

Publication Number Publication Date
US20010006635A1 true US20010006635A1 (en) 2001-07-05

Family

ID=26673252

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/722,659 Abandoned US20010006635A1 (en) 1995-09-29 1996-09-27 Use of heparinase to decrease inflammatory responses
US11/118,477 Abandoned US20050191288A1 (en) 1995-09-29 2005-05-02 Use of heparinase to decrease inflammatory responses
US11/357,967 Expired - Fee Related US7264799B2 (en) 1995-09-29 2006-02-22 Use of heparinases to decrease inflammatory response

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/118,477 Abandoned US20050191288A1 (en) 1995-09-29 2005-05-02 Use of heparinase to decrease inflammatory responses
US11/357,967 Expired - Fee Related US7264799B2 (en) 1995-09-29 2006-02-22 Use of heparinases to decrease inflammatory response

Country Status (11)

Country Link
US (3) US20010006635A1 (de)
EP (2) EP1552846A3 (de)
JP (1) JP3713276B2 (de)
AT (1) ATE273020T1 (de)
AU (1) AU703394B2 (de)
CA (1) CA2233343A1 (de)
DE (1) DE69633127T2 (de)
DK (1) DK0852491T3 (de)
ES (1) ES2227611T3 (de)
PT (1) PT852491E (de)
WO (1) WO1997011684A1 (de)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20040006008A1 (en) * 2001-04-30 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20050281805A1 (en) * 2002-05-29 2005-12-22 Symbiontics, Inc. Targeted therapeutic proteins
US20070098708A1 (en) * 2005-11-03 2007-05-03 James Myette Heparan sulfate glycosaminoglycan lyase and uses thereof
US20070134226A1 (en) * 2005-11-03 2007-06-14 James Myette Heparan sulfate glycosaminoglycan lyase and uses thereof
US20080171367A1 (en) * 2006-11-03 2008-07-17 Momenta Pharmaceuticals, Inc. Heparan Sulfate Glycosaminoglycan Lyase and Uses Thereof
US20080241118A1 (en) * 2001-10-16 2008-10-02 Zystor Therapeutics, Inc. Methods and Compositions for Targeting Proteins Across the Blood Brain Barrier
US20080299640A1 (en) * 2004-02-10 2008-12-04 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
US20110223147A1 (en) * 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153187A (en) * 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
CA2242693C (en) * 1997-09-04 2002-09-17 Becton, Dickinson And Company Additive formulation and method of use thereof
JP2002504376A (ja) 1998-02-24 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー ヒト血小板ヘパラナーゼポリペプチド、それをコードするポリヌクレオチド分子、およびヘパラナーゼ活性を改変する化合物の同定方法
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
EP1010762A1 (de) * 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNS-Konstrukte von Blutgerinnungsfaktoren und P-Selektin
EP1026250A1 (de) * 1998-12-02 2000-08-09 Aventis Behring GmbH DNs-Konstructs von Blutgerinnungsfaktoren und P-Selektin
CA2393855A1 (en) 1999-12-22 2001-06-28 Oxford Glycosciences (Uk) Ltd. Homologues of human heparanase and splice variants thereof
ES2527853T3 (es) * 2000-03-08 2015-01-30 Massachusetts Institute Of Technology Heparinasa III y sus usos
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2005074655A2 (en) * 2004-01-30 2005-08-18 Emory University Materials and method for promotion of nerve regeneration
CN1312183C (zh) * 2004-05-19 2007-04-25 清华大学 一种肝素酶i融合蛋白及其编码基因与表达方法
CN100344769C (zh) * 2005-08-04 2007-10-24 清华大学 一种制备低分子量肝素的方法
WO2014131470A1 (en) * 2013-02-28 2014-09-04 Kao Corporation Composition and process for semi-permanent straightening of hair
JP7330893B2 (ja) 2017-03-10 2023-08-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
JP2021528421A (ja) 2018-06-20 2021-10-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 細胞保護の方法と組成物
WO2021097345A1 (en) * 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941664A (en) * 1959-02-19 1963-11-13 Henry Thompson Stanton Jr Buccal or sublingual tablet containing carbohydra e enzyme for controlling inflammation
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
US5169772A (en) * 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
KR927003090A (ko) * 1989-08-23 1992-12-17 하다사 메디칼 오르가니제이션 헤파린효소를 포함하는 상처 치유 약제
US5099855A (en) 1989-11-09 1992-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Methods of and apparatus for monitoring respiration and conductive gel used therewith
EP0546077A1 (de) * 1990-08-27 1993-06-16 Chiron Corporation Cd18-peptid arzneimittel zur behandlung von krankheiten
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
US5714376A (en) * 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
DK75593D0 (de) 1993-06-25 1993-06-25 Novo Nordisk As
EP0726773A1 (de) * 1993-11-17 1996-08-21 Massachusetts Institute Of Technology Verfahren zur hemmung der angiogenese mittels heparinase
US5997863A (en) * 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396811B2 (en) 2001-04-30 2008-07-08 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
US20090203575A1 (en) * 2001-04-30 2009-08-13 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040006008A1 (en) * 2001-04-30 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US9814762B2 (en) 2001-04-30 2017-11-14 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US8859498B2 (en) 2001-04-30 2014-10-14 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US8492338B2 (en) 2001-04-30 2013-07-23 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US10300113B2 (en) 2001-04-30 2019-05-28 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US8492337B2 (en) 2001-04-30 2013-07-23 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7858576B2 (en) 2001-04-30 2010-12-28 Zystor Therapeutics, Inc. Method for targeting lysosomal enzymes
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20090029467A1 (en) * 2001-04-30 2009-01-29 Zystor Therapeutics, Inc. Method for targeting lysosomal enzymes
US20080241118A1 (en) * 2001-10-16 2008-10-02 Zystor Therapeutics, Inc. Methods and Compositions for Targeting Proteins Across the Blood Brain Barrier
US7981864B2 (en) 2001-10-16 2011-07-19 Biomarin Pharmaceutical Inc. Methods and compositions for targeting proteins across the blood brain barrier
US8207114B2 (en) 2002-05-29 2012-06-26 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
US20100075906A1 (en) * 2002-05-29 2010-03-25 Zystor Therapeutics, Inc. Targeted Therapeutic Proteins
US20050281805A1 (en) * 2002-05-29 2005-12-22 Symbiontics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20080299640A1 (en) * 2004-02-10 2008-12-04 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US7785856B2 (en) 2004-02-10 2010-08-31 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20110104814A1 (en) * 2005-11-03 2011-05-05 James Myette Heparan sulfate glycosaminoglycan lyase and uses thereof
US7888072B2 (en) 2005-11-03 2011-02-15 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US20070098708A1 (en) * 2005-11-03 2007-05-03 James Myette Heparan sulfate glycosaminoglycan lyase and uses thereof
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US8198050B2 (en) 2005-11-03 2012-06-12 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US20080171375A1 (en) * 2005-11-03 2008-07-17 Momenta Pharmaceuticals, Inc., A Delaware Corporation Heparan Sulfate Glycosaminoglycan Lyase and Uses Thereof
US20070134226A1 (en) * 2005-11-03 2007-06-14 James Myette Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691612B2 (en) 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US20080171367A1 (en) * 2006-11-03 2008-07-17 Momenta Pharmaceuticals, Inc. Heparan Sulfate Glycosaminoglycan Lyase and Uses Thereof
US7691613B2 (en) 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
US20110223147A1 (en) * 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US9469683B2 (en) 2008-05-07 2016-10-18 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US8563691B2 (en) 2008-05-07 2013-10-22 Biomarin Pharmaceutical, Inc. Lysosomal targeting peptides and uses thereof
US11351231B2 (en) 2008-05-07 2022-06-07 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes

Also Published As

Publication number Publication date
AU703394B2 (en) 1999-03-25
EP0852491B1 (de) 2004-08-11
PT852491E (pt) 2004-11-30
ATE273020T1 (de) 2004-08-15
DK0852491T3 (da) 2004-12-20
DE69633127T2 (de) 2005-08-04
EP0852491A4 (de) 2002-08-07
CA2233343A1 (en) 1997-04-03
JPH11512721A (ja) 1999-11-02
DE69633127D1 (de) 2004-09-16
EP0852491A1 (de) 1998-07-15
US20050191288A1 (en) 2005-09-01
ES2227611T3 (es) 2005-04-01
JP3713276B2 (ja) 2005-11-09
AU7379196A (en) 1997-04-17
WO1997011684A1 (en) 1997-04-03
US7264799B2 (en) 2007-09-04
US20060140928A1 (en) 2006-06-29
EP1552846A2 (de) 2005-07-13
EP1552846A3 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
US7264799B2 (en) Use of heparinases to decrease inflammatory response
EP0769961B1 (de) Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren
Handagama et al. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules.
US6022854A (en) Platelet specific therapeutic compound and method of treating
Handagama et al. Kistrin, an integrin antagonist, blocks endocytosis of fibrinogen into guinea pig megakaryocyte and platelet alpha-granules.
Nourshargh et al. Accumulation of 111In-neutrophils in rabbit skin in allergic and non-allergic inflammatory reactions in vivo. Inhibition by neutrophil pretreatment in vitro with a monoclonal antibody recognizing the CD18 antigen.
Smedsrød et al. Studies in vivo and in vitro on the uptake and degradation of soluble collagen α1 (I) chains in rat liver endothelial and Kupffer cells
US20020099000A1 (en) Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
Saba et al. Reversal of opsonic deficiency in surgical, trauma, and burn patients by infusion of purified human plasma fibronectin. Correlation with experimental observations
AU659432B2 (en) A method for the inhibition or prevention of tumor cell metastasis with hirudin
AU702976B2 (en) Prodrug compositions and drug delivery methods using synthetic receptors
Handagama et al. Endocytosis of fibrinogen into hamster megakaryocyte alpha granules is dependent on a dimeric gamma A configuration
US7674466B2 (en) Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1
VELKY et al. Plasma fibronectin response to sepsis: mobilization or synthesis?
AU754117B2 (en) Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
Liebman et al. Human Growth Factor/Immunoglobulin Complexes for Treatment of Myocardial Ischemia-Reperfusion Injury
Sherry Fibrinolytic agents

Legal Events

Date Code Title Description
AS Assignment

Owner name: IBEX TECHNOLOGIES INC., CANADA

Free format text: ;ASSIGNORS:BENNETT, D. CLARK;CAUCHON, ELIZABETH;FINK, DOMINIQUE;AND OTHERS;REEL/FRAME:008623/0914;SIGNING DATES FROM 19970327 TO 19970602

AS Assignment

Owner name: IBEX TECHNOLOGIES INC., CANADA

Free format text: RECORD TO CORRECT SERIAL NUMBER PREVIOUSLY RECORDED ON REEL 8623 FRAME 914.;ASSIGNORS:BENNETT, D. CLARK;CAUCHON, ELIZABETH;FINK, DOMINIQUE;AND OTHERS;REEL/FRAME:008857/0657;SIGNING DATES FROM 19970327 TO 19970602

AS Assignment

Owner name: BIOMARIN PHARMACEUTICALS INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOMARIN ENZYMES, INC.;REEL/FRAME:014405/0059

Effective date: 20030807

AS Assignment

Owner name: BIOMARIN PHARMACEUTICAL INC., CALIFORNIA

Free format text: CORRECT COVER SHEET TO CORRECT SERIAL NUMBER, PREVIOUSLY RECORDED AT REEL/FRAME 014405/0059 (ASSIGNMENT OF ASSIGNOR'S INTEREST);ASSIGNOR:BIOMARIN ENZYMES, INC.;REEL/FRAME:015320/0148

Effective date: 20030807

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION